---
title: "LifeSci Capital Remains a Buy on Ibio (IBIO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648765.md"
description: "LifeSci Capital's Patrick Dolezal has maintained a Buy rating on Ibio (IBIO) with a price target of $5.00. The analyst consensus for Ibio is a Strong Buy, with an average price target of $5.80. Dolezal has an average return of 15.0% and a 43.63% success rate on his stock recommendations."
datetime: "2026-05-16T14:36:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648765.md)
  - [en](https://longbridge.com/en/news/286648765.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648765.md)
generator: "portal-rs"
---

# LifeSci Capital Remains a Buy on Ibio (IBIO)

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Ibio, with a price target of $5.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Dolezal covers the Healthcare sector, focusing on stocks such as Ibio, Neurogene, and Rocket Pharmaceuticals. According to TipRanks, Dolezal has an average return of 15.0% and a 43.63% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ibio with a $5.80 average price target.

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [NGNE.US](https://longbridge.com/en/quote/NGNE.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [iBio Advances to Clinical Stage With IBIO-600 Trial](https://longbridge.com/en/news/282052903.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**